PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial...
12 insider purchases on record · latest filing 2025-10-01.
Insiders have also filed 31 sale transactions at PEPG.